Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA - a podcast by BMJ Group

Atul Deodhar, from the Oregon Health&Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.

Further episodes of ARD podcast

Further podcasts by BMJ Group

Website of BMJ Group